Genomic Health Inc (GHDX) - Product Pipeline Analysis, 2019 Update

Summary

Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The companys commercial product portfolio comprises Onco type DX breast cancer test, Onco type DX colon cancer test, Onco type DX prostate cancer test and Oncotype SEQ Liquid Select liquid biopsy mutation panel. Genomic Health develops these products using its Oncotype IQ Genomic Intelligence Platform, a technology which uses RT-PCR approach to improve cancer treatment decisions. The company has operations in North America, Europe and Asia through direct offices, subsidiaries and distributors. Genomic Health is headquartered in Redwood City, California, the US.

This report is a source for data, analysis, and actionable intelligence on the companys portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Genomic Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company


List of Tables
List of Figures
Genomic Health Inc Company Overview
Genomic Health Inc Company Snapshot
Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Genomic Health Inc Pipeline Analysis Overview
Business Description
Genomic Health Inc - Key Facts
Genomic Health Inc - Major Products and Services
Genomic Health Inc Pipeline Products by Development Stage
Genomic Health Inc Ongoing Clinical Trials by Trial Status
Genomic Health Inc Pipeline Products Overview
Diagnostic Test - Non Small Cell Lung Cancer
Diagnostic Test - Non Small Cell Lung Cancer Product Overview
Liquid Biopsy-Based Bladder Cancer Test
Liquid Biopsy-Based Bladder Cancer Test Product Overview
Negative Biopsy Test - Prostate Cancer
Negative Biopsy Test - Prostate Cancer Product Overview
Next Generation Sequencing Oncotype DX - Prostate Cancer Assay
Next Generation Sequencing Oncotype DX - Prostate Cancer Assay Product Overview
Oncotype Dx - Kidney Cancer
Oncotype Dx - Kidney Cancer Product Overview
Oncotype Dx Colon Cancer Assay - Oxaliplatin
Oncotype Dx Colon Cancer Assay - Oxaliplatin Product Overview
Oncotype DX IVD Test
Oncotype DX IVD Test Product Overview
Oncotype DX IVD Test Clinical Trial
Oncotype SEQ - Tissue Mutation Panel
Oncotype SEQ - Tissue Mutation Panel Product Overview
Oncotype TRACK
Oncotype TRACK Product Overview
Prognostic Test - Melanoma
Prognostic Test - Melanoma Product Overview
Prognostic Test - Non-Metastatic Renal Cell Carcinoma
Prognostic Test - Non-Metastatic Renal Cell Carcinoma Product Overview
Genomic Health Inc - Key Competitors
Genomic Health Inc - Key Employees
Genomic Health Inc - Key Employee Biographies
Genomic Health Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Genomic Health Inc, Recent Developments
Jun 04, 2019: Secondary analysis of landmark TAILORx results, published in The New England Journal of Medicine, affirms unique ability of Oncotype DX Breast Recurrence Score Test to predict chemotherapy benefit, guiding adjuvant therapy with even greater precision
Jun 03, 2019: Updated ASCO guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit with the Oncotype DX Breast Recurrence Score Test in node-negative Breast Cancer
May 07, 2019: Genomic Health announces first quarter 2019 financial results
Mar 25, 2019: New long-term outcomes data presented at St. Gallen International Breast Cancer Conference reinforce TAILORx treatment paradigm and standard of care use for Oncotype DX Breast Recurrence Score test
Feb 20, 2019: Genomic Health reports record 2018 fourth quarter and year-end financial results and provides 2019 financial guidance
Feb 05, 2019: Oncotype DX Genomic Prostate Score established as first genomic test with prospective validation for predicting adverse pathology in newly diagnosed patients
Jan 23, 2019: Gene-expression profiling raises costs for cancer care without improving outcomes for low-risk breast cancer patients, according to researchers
Jan 14, 2019: NICE Issues Diagnostics Guidance on Tumour Profiling Tests to Guide Adjuvant Chemotherapy Decisions in Early Breast Cancer
Jan 07, 2019: Genomic Health marks more than 1 million patients worldwide who have benefited from Oncotype DX testing in personalizing cancer treatment decisions to improve outcomes
Dec 19, 2018: NICE Expands recommendation for the Oncotype DX Breast Recurrence Score Test to more patients with early-stage breast cancer within the United Kingdom
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List Of Tables

List of Tables
Genomic Health Inc Pipeline Products and Ongoing Clinical Trials Overview
Genomic Health Inc Pipeline Products by Equipment Type
Genomic Health Inc Pipeline Products by Indication
Genomic Health Inc Ongoing Clinical Trials by Trial Status
Genomic Health Inc, Key Facts
Genomic Health Inc, Major Products and Services
Genomic Health Inc Number of Pipeline Products by Development Stage
Genomic Health Inc Pipeline Products Summary by Development Stage
Genomic Health Inc Ongoing Clinical Trials by Trial Status
Genomic Health Inc Ongoing Clinical Trials Summary
Diagnostic Test - Non Small Cell Lung Cancer - Product Status
Diagnostic Test - Non Small Cell Lung Cancer - Product Description
Liquid Biopsy-Based Bladder Cancer Test - Product Status
Liquid Biopsy-Based Bladder Cancer Test - Product Description
Negative Biopsy Test - Prostate Cancer - Product Status
Negative Biopsy Test - Prostate Cancer - Product Description
Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Status
Next Generation Sequencing Oncotype DX - Prostate Cancer Assay - Product Description
Oncotype Dx - Kidney Cancer - Product Status
Oncotype Dx - Kidney Cancer - Product Description
Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Status
Oncotype Dx Colon Cancer Assay - Oxaliplatin - Product Description
Oncotype DX IVD Test - Product Status
Oncotype DX IVD Test - Product Description
Oncotype DX IVD Test - An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-receptor Positive/HER2-Negative Primary Breast Cancer
Oncotype SEQ - Tissue Mutation Panel - Product Status
Oncotype SEQ - Tissue Mutation Panel - Product Description
Oncotype TRACK - Product Status
Oncotype TRACK - Product Description
Prognostic Test - Melanoma - Product Status
Prognostic Test - Melanoma - Product Description
Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Status
Prognostic Test - Non-Metastatic Renal Cell Carcinoma - Product Description
Genomic Health Inc, Key Employees
Genomic Health Inc, Key Employee Biographies
Genomic Health Inc, Other Locations
Genomic Health Inc, Subsidiaries
Glossary

List Of Figures

List of Figures
Genomic Health Inc Pipeline Products by Equipment Type
Genomic Health Inc Pipeline Products by Development Stage
Genomic Health Inc Ongoing Clinical Trials by Trial Status

GenomicTree Inc (228760) - Product Pipeline Analysis, 2019 Update

GenomicTree Inc (GenomicTree) is a medical device company that develops and commercializes diagnostic products for the screening and diagnosis of cancer. The company also provides non-invasive cancer molecular diagnostic product.

USD 750 View Report

Genomic Health Inc (GHDX) - Product Pipeline Analysis, 2019 Update

Genomic Health Inc (Genomic Health) is a provider of genomic-based diagnostic tests and clinical laboratory services for the diagnosis of cancer. The companys commercial product portfolio comprises Onco type DX

USD 750 View Report

Harrow Health Inc (IMMY) - Financial and Strategic SWOT Analysis Review

Harrow Health Inc (IMMY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been compiled to

USD 125 View Report

Proteus Digital Health Inc - Product Pipeline Analysis, 2019 Update

Proteus Digital Health Inc (Proteus) is a medical equipment company that develops and sells technology solutions for improving clinical outcomes. The company developed novel category of pharmaceuticals through in-house research

USD 750 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available